Erschienen in:
01.11.2015 | Case Report
Romiplostim for secondary thrombocytopenia following allogeneic stem cell transplantation in children
verfasst von:
Natalia Maximova, D. Zanon, F. Rovere, A. Maestro, G. Schillani, R. Paparazzo
Erschienen in:
International Journal of Hematology
|
Ausgabe 5/2015
Einloggen, um Zugang zu erhalten
Abstract
The outcome of romiplostim for secondary failure of platelet recovery (SFPR) was investigated in children who had undergone hematopoietic stem cell transplantation (HSCT). Seven transfusion-dependent pediatric patients (median age 11 years), with platelet counts below 10 × 109/L, received four weekly doses of subcutaneous romiplostim to treat SFPR developed after HSCT. All patients, except one (patient 4), became platelet transfusion-independent in the second week from the beginning of treatment and no patient needed to discontinue drug treatment because of adverse events. Romiplostim could represent a beneficial first-line treatment, but further studies are required.